These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 27053454)

  • 61. [Salt-induced inappropriate augmentation of intrarenal RAAS and its treatment in patients with chronic kidney disease].
    Konishi Y
    Nihon Rinsho; 2012 Sep; 70(9):1588-92. PubMed ID: 23012808
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Challenges in Treating Cardiovascular Disease: Restricting Sodium and Managing Hyperkalemia.
    Clegg DJ; Cody M; Palmer BF
    Mayo Clin Proc; 2017 Aug; 92(8):1248-1260. PubMed ID: 28778258
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.
    Soares AE; Maes M; Godeny P; Matsumoto AK; Barbosa DS; da Silva TAF; Souza FHMO; Delfino VDA
    Life Sci; 2017 Dec; 191():175-179. PubMed ID: 29079468
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.
    Kuo KL; Hung SC; Liu JS; Chang YK; Hsu CC; Tarng DC
    Sci Rep; 2015 Nov; 5():17150. PubMed ID: 26612282
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cardiorenal syndrome in chronic kidney disease.
    Tsuruya K; Eriguchi M
    Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):154-62. PubMed ID: 25636143
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study.
    Noh Y; Lee J; Shin S; Park I; Bae SK; Oh E; Lee S
    Int J Clin Pharm; 2018 Feb; 40(1):160-168. PubMed ID: 29282632
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Novel drugs and intervention strategies for the treatment of chronic kidney disease.
    Lambers Heerspink HJ; de Zeeuw D
    Br J Clin Pharmacol; 2013 Oct; 76(4):536-50. PubMed ID: 23802504
    [TBL] [Abstract][Full Text] [Related]  

  • 68. From Cardiorenal Syndrome to Chronic Cardiovascular and Kidney Disorder: A Conceptual Transition.
    Zoccali C; Mallamaci F; Halimi JM; Rossignol P; Sarafidis P; De Caterina R; Giugliano R; Zannad F
    Clin J Am Soc Nephrol; 2024 Jun; 19(6):813-820. PubMed ID: 37902772
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [New potassium binders effective: treatment of hyperkalaemia secondary to RAAS inhibitors].
    Hoorn EJ
    Ned Tijdschr Geneeskd; 2015; 159():A8801. PubMed ID: 25761299
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?
    Dubin RF; Shah SJ
    Curr Heart Fail Rep; 2016 Jun; 13(3):132-9. PubMed ID: 27118234
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients.
    Georgianos PI; Sarafidis PA; Lasaridis AN
    Curr Vasc Pharmacol; 2015; 13(2):229-38. PubMed ID: 24007427
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease.
    Nishiyama A
    Hypertens Res; 2019 Mar; 42(3):293-300. PubMed ID: 30523293
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Awareness and Knowledge Among Internal Medicine House-Staff for Dose Adjustment of Cardiovascular Drugs in Chronic Kidney Disease.
    D'Angelo K; Paul S; Ranjeeta F; Fogel J; Chikvashvili D; Rubinstein S
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):177-184. PubMed ID: 33625694
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association between Parathyroid Hormone and Cardiovascular Disease.
    Fujii H
    Ther Apher Dial; 2018 Jun; 22(3):236-241. PubMed ID: 29707916
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design and optimization strategies for the development of new drugs that treat chronic kidney disease.
    Ramos AM; Fernández-Fernández B; Pérez-Gómez MV; Carriazo Julio SM; Sanchez-Niño MD; Sanz A; Ruiz-Ortega M; Ortiz A
    Expert Opin Drug Discov; 2020 Jan; 15(1):101-115. PubMed ID: 31736379
    [No Abstract]   [Full Text] [Related]  

  • 76. Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy.
    Law JP; Price AM; Pickup L; Radhakrishnan A; Weston C; Jones AM; McGettrick HM; Chua W; Steeds RP; Fabritz L; Kirchhof P; Pavlovic D; Townend JN; Ferro CJ
    J Am Heart Assoc; 2020 Apr; 9(7):e016041. PubMed ID: 32212912
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review.
    Salman IM
    Curr Hypertens Rep; 2015 Aug; 17(8):59. PubMed ID: 26071764
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cardio-renal syndromes: from foggy bottoms to sunny hills.
    Ronco C
    Heart Fail Rev; 2011 Nov; 16(6):509-17. PubMed ID: 21259069
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Emerging therapies for chronic kidney disease: what is their role?
    Vilayur E; Harris DC
    Nat Rev Nephrol; 2009 Jul; 5(7):375-83. PubMed ID: 19455178
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Use of Genomics to Drive Kidney Disease Drug Discovery and Development.
    Reilly DF; Breyer MD
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1342-1351. PubMed ID: 32193173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.